Biopharmaceutical company BioVersys has announced the grant of key patent claims in China for BV100, the intravenous ...

Beneath a patch of soil in Hamilton, Ontario, scientists may have found a long-awaited answer to one of medicine’s most pressing problems. They found a new molecule named lariocidin—a potential new ...

Single-Molecule Footprinting reveals that RNA polymerase II (Pol II) occupancy is infrequent at mouse promoters. This results ...

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by ...

Strong revenue performance, including approximately $1.9 million milestone and license ... Dyadic has developed and validated prototypes for four additional enzymes, including RNase Inhibitors and T7 ...

Strong revenue performance, including approximately $1.9 million milestone and license ... Dyadic has developed and validated prototypes for four additional enzymes, including RNase Inhibitors and T7 ...

To implement the blueprint it contains, RNA polymerase is used. The enzyme reads the information stored in the template and makes the corresponding RNA component. Algorithms specifically developed ...